A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants

被引:138
|
作者
Dearlove, Bethany [1 ,2 ,3 ,4 ]
Lewitus, Eric [1 ,2 ,3 ,4 ]
Bai, Hongjun [1 ,2 ,3 ,4 ]
Li, Yifan [1 ,2 ,3 ,4 ]
Reeves, Daniel B. [5 ]
Joyce, M. Gordon [1 ,3 ]
Scott, Paul T. [1 ]
Amare, Mihret F. [1 ,3 ]
Vasan, Sandhya [2 ,3 ,4 ]
Michael, Nelson L. [4 ]
Modjarrad, Kayvon [1 ,4 ]
Rolland, Morgane [1 ,2 ,3 ,4 ]
机构
[1] Walter Reed Army Inst Res, Emerging Infect Dis Branch, Silver Spring, MD 20910 USA
[2] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA
[3] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA
[4] Walter Reed Army Inst Res, Ctr Infect Dis Res, Silver Spring, MD 20910 USA
[5] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA
关键词
SARS-CoV-2; evolution; vaccine; MODEL; GLYCOPROTEIN; MUTATIONS; DIVERSITY; ALGORITHM; EVOLUTION; INFECTION; GENOME; SITE; TREE;
D O I
10.1073/pnas.2008281117
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The magnitude of the COVID-19 pandemic underscores the urgency for a safe and effective vaccine. Many vaccine candidates focus on the Spike protein, as it is targeted by neutralizing antibodies and plays a key role in viral entry. Here we investigate the diversity seen in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences and compare it to the sequence on which most vaccine candidates are based. Using 18,514 sequences, we perform phylogenetic, population genetics, and structural bioinformatics analyses. We find limited diversity across SARS-CoV-2 genomes: Only 11 sites show polymorphisms in >5% of sequences; yet two mutations, including the D614G mutation in Spike, have already become consensus. Because SARS-CoV-2 is being transmitted more rapidly than it evolves, the viral population is becoming more homogeneous, with a median of seven nucleotide substitutions between genomes. There is evidence of purifying selection but little evidence of diversifying selection, with substitution rates comparable across structural versus nonstructural genes. Finally, the Wuhan-Hu-1 reference sequence for the Spike protein, which is the basis for different vaccine candidates, matches optimized vaccine inserts, being identical to an ancestral sequence and one mutation away from the consensus. While the rapid spread of the D614G mutation warrants further study, our results indicate that drift and bottleneck events can explain the minimal diversity found among SARS-CoV-2 sequences. These findings suggest that a single vaccine candidate should be efficacious against currently circulating lineages.
引用
收藏
页码:23652 / 23662
页数:11
相关论文
共 50 条
  • [41] Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance
    Dholariya, Sagar
    Parchwani, Deepak Narayan
    Singh, Ragini
    Sonagra, Amit
    Motiani, Anita
    Patel, Digishaben
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (04) : 451 - 458
  • [42] Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants
    Cheng, Hoi Lok
    Lim, Sing Mei
    Jia, Huan
    Chen, Ming Wei
    Ng, Say Yong
    Gao, Xiaohong
    Somani, Jyoti
    Sengupta, Sharmila
    Tay, Dousabel M. Y.
    Chua, Patrina W. L.
    Abirami, R.
    Ling, Sharon Y. H.
    McBee, Megan E.
    Young, Barnaby E.
    Sikes, Hadley D.
    Preiser, Peter R.
    MICROBIOLOGY SPECTRUM, 2022, 10 (05):
  • [43] Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
    Deliyannis, Georgia
    Gherardin, Nicholas A.
    Wong, Chinn Yi
    Grimley, Samantha L.
    Cooney, James P.
    Redmond, Samuel J.
    Ellenberg, Paula
    Davidson, Kathryn C.
    Mordant, Francesca L.
    Smith, Tim
    Gillard, Marianne
    Lopez, Ester
    McAuley, Julie
    Tan, Chee Wah
    Wang, Jing J.
    Zeng, Weiguang
    Littlejohn, Mason
    Zhou, Runhong
    Chan, Jasper Fuk-Woo
    Chen, Zhi-wei
    Hartwig, Airn E.
    Bowen, Richard
    Mackenzie, Jason M.
    Vincan, Elizabeth
    Torresi, Joseph
    Kedzierska, Katherine
    Pouton, Colin W.
    Gordon, Tom P.
    Wang, Lin-fa
    Kent, Stephen J.
    Wheatley, Adam K.
    Lewin, Sharon R.
    Subbarao, Kanta
    Chung, Amy W.
    Pellegrini, Marc
    Munro, Trent
    Nolan, Terry
    Rockman, Steven
    Jackson, David C.
    Purcell, Damian F. J.
    Godfrey, Dale I.
    EBIOMEDICINE, 2023, 92
  • [44] Identification of SARS-CoV-2 variants of concern in vaccine-breakthrough infections
    Abdalhamid, Baha
    Donahue, Matthew
    Kamal-Ahmed, Ishrat
    Strand, Kyle
    Mitchell, Elizabeth
    Iwen, Peter C.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2022, 16 (04): : 580 - 582
  • [45] Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections
    Ahmad, Liyana
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [46] The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development
    Hajissa, Khalid
    Mussa, Ali
    Karobari, Mohmed Isaqali
    Abbas, Muhammad Adamu
    Ibrahim, Ibrahim Khider
    Assiry, Ali A.
    Iqbal, Azhar
    Alhumaid, Saad
    Mutair, Abbas Al
    Rabaan, Ali A.
    Messina, Pietro
    Scardina, Giuseppe Alessandro
    VACCINES, 2022, 10 (08)
  • [47] Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
    Chatterjee, Bhaswati
    Thakur, Suman S.
    EXPERT REVIEW OF VACCINES, 2022, 21 (01) : 47 - 67
  • [48] Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
    Rayati Damavandi, Amirmasoud
    Dowran, Razieh
    Al Sharif, Sarah
    Kashanchi, Fatah
    Jafari, Reza
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2022, 211 (2-3) : 79 - 103
  • [49] SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
    Pather, Shanti
    Madhi, Shabir A.
    Cowling, Benjamin J.
    Moss, Paul
    Kamil, Jeremy P.
    Ciesek, Sandra
    Muik, Alexander
    Tuereci, Oezlem
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
    Gardner, Billy J.
    Kilpatrick, A. Marm
    VIRUSES-BASEL, 2024, 16 (03):